Imatinib Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
AVTE | D | Aerovate Therapeutics, Inc. | 1.75 | |
IKT | D | Inhibikase Therapeutics, Inc. | 1.60 | |
COGT | F | Cogent Biosciences, Inc. | -8.10 |
Related Industries: Biotechnology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 1.19 | |
XBI | D | SPDR S&P Biotech ETF | 0.56 | |
LABU | F | Direxion Daily S&P Biotech Bull 3X Shares | 0.44 | |
SBIO | D | ALPS Medical Breakthroughs ETF | 0.44 | |
BTEC | D | Principal Healthcare Innovators Index ETF | 0.35 |
Compare ETFs
Date | Stock | Title |
---|---|---|
Apr 19 | IKT | Inhibikase Therapeutics files to sell common stock, warrants |
- Imatinib
Imatinib, sold under the brand name Gleevec among others, is an oral chemotherapy medication used to treat cancer. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. It is taken by mouth.Common side effects include vomiting, diarrhea, muscle pain, headache, and rash. Severe side effects may include fluid retention, gastrointestinal bleeding, bone marrow suppression, liver problems, and heart failure. Use during pregnancy may result in harm to the fetus. Imatinib works by stopping the Bcr-Abl tyrosine-kinase. This can slow growth or result in programmed cell death of certain types of cancer cells.Imatinib was approved for medical use in the United States in 2001. It is on the World Health Organization's List of Essential Medicines. A generic version became available in the UK as of 2017.
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Featured Articles